We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 2 Reduction of Dietary Mycotoxin Exposure by ACCS100" (RDMEACCS100)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01677195
First Posted: August 31, 2012
Last Update Posted: April 19, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Texas A&M University
University of Georgia
The University of Texas at San Antonio
Information provided by (Responsible Party):
Texas Enterosorbents Incorporated
Results First Submitted: December 14, 2015  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double (Participant, Investigator);   Primary Purpose: Prevention
Condition: Dietary Carcinogenesis
Interventions: Drug: ACCS100
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Randomized, double blind, placebo controlled clinical trial of ACCS100 for the prevention of cancer associated with dietary Aflatoxin exposure. Recruitment occurred in Bexar and Medina Counties, Texas, USA from August 2012 through August 2014. The number of participants was 234 and 143 finished the study.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
ACCS100 High Dose

Participants will receive a total daily dose of 3 grams of ACCS100; 1 gram three times a day with meals.

ACCS100: ACCS100 is not absorbed. The dose is estimated based on the volume of the gastrointestinal tract. We estimate that the average human intestinal tract has a volume of approximately 4 liters. In the high dose group, the effective concentration in the gut is 0.75 milligrams per milliliter. In the low dose, the effective concentration in the gut is 0.375 milligrams per milliliter. The test article is made by filling gelatin capsules with 500 milligrams of ACCS100. There are no excipients used in the manufacturing process of the test article.
ACCS100 Low Dose

Participants will receive a total daily dose of 1.5 grams of ACCS100; 500 mgs three times a day with meals.

ACCS100: ACCS100 is not absorbed. The dose is estimated based on the volume of the gastrointestinal tract. We estimate that the average human intestinal tract has a volume of approximately 4 liters. In the high dose group, the effective concentration in the gut is 0.75 milligrams per milliliter. In the low dose, the effective concentration in the gut is 0.375 milligrams per milliliter. The test article is made by filling gelatin capsules with 500 milligrams of ACCS100. There are no excipients used in the manufacturing process of the test article.
Placebo

Participants will receive placebo capsules shown not to absorb mycotoxins three times a day with meals.

Placebo: Placebo is calcium carbonate, USP. This calcium mineral does not absorb mycotoxins, specifically aflatoxin and fumonisin. This mineral has approximately the same physical appearance as active test article.

Participant Flow:   Overall Study
    ACCS100 High Dose   ACCS100 Low Dose   Placebo
STARTED   71   83   80 
COMPLETED   42   51   50 
NOT COMPLETED   29   32   30 
Lost to Follow-up                14                22                22 
Withdrawal by Subject                1                0                1 
Adverse Event                6                4                1 
Physician Decision                1                2                2 
Pregnancy                0                1                0 
Protocol Violation                7                3                4 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Participants had detectable levels of aflatoxin in serum sample and were otherwise healthy.

Reporting Groups
  Description
ACCS100 High Dose

Participants will receive a total daily dose of 3 grams of ACCS100; 1 gram three times a day with meals.

ACCS100: ACCS100 is not absorbed. The dose is estimated based on the volume of the gastrointestinal tract. We estimate that the average human intestinal tract has a volume of approximately 4 liters. In the high dose group, the effective concentration in the gut is 0.75 milligrams per milliliter. In the low dose, the effective concentration in the gut is 0.375 milligrams per milliliter. The test article is made by filling gelatin capsules with 500 milligrams of ACCS100. There are no excipients used in the manufacturing process of the test article.
ACCS100 Low Dose

Participants will receive a total daily dose of 1.5 grams of ACCS100; 500 mgs three times a day with meals.

ACCS100: ACCS100 is not absorbed. The dose is estimated based on the volume of the gastrointestinal tract. We estimate that the average human intestinal tract has a volume of approximately 4 liters. In the high dose group, the effective concentration in the gut is 0.75 milligrams per milliliter. In the low dose, the effective concentration in the gut is 0.375 milligrams per milliliter. The test article is made by filling gelatin capsules with 500 milligrams of ACCS100. There are no excipients used in the manufacturing process of the test article.
Placebo

Participants will receive placebo capsules shown not to absorb mycotoxins three times a day with meals.

Placebo: Placebo is calcium carbonate, USP. This calcium mineral does not absorb mycotoxins, specifically aflatoxin and fumonisin. This mineral has approximately the same physical appearance as active test article.
Total Total of all reporting groups

Baseline Measures
   ACCS100 High Dose   ACCS100 Low Dose   Placebo   Total 
Overall Participants Analyzed 
[Units: Participants]
 		 71   83   80   234 
Age 
[Units: Participants]
 		       
<=18 years   0   0   0   0 
Between 18 and 65 years   71   83   80   234 
>=65 years   0   0   0   0 
Age 
[Units: Years]
Mean (Standard Deviation) 		 41.1  (13.8)   39.2  (13.9)   42.2  (13.6)   41.1  (13.8) 
Gender 
[Units: Participants]
 		       
Female   53   63   64   180 
Male   18   20   16   54 
Region of Enrollment 
[Units: Participants]
 		       
United States   71   83   80   234 


  Outcome Measures

1.  Primary:   AFB1-lysine Adduct (pg/mg) Overtime   [ Time Frame: 3 months on intervention (weeks 0-12); 1 month off intervention (week 16) ]
  Show Outcome Measure 1


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Unlike our clinical trials in Africa, where maximum compliance was achieved through the daily in-home monitoring, the current study relied on participant reports during monthly visits in which total compliance was difficult to assess.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Dr. Bradley H. Pollock, PI
Organization: University of Texas Health Science Center at San Antonio / University of California, Davis* current
phone: (530) 752-7250
e-mail: pbollock@ucdavis.edu


Publications:


Responsible Party: Texas Enterosorbents Incorporated
ClinicalTrials.gov Identifier: NCT01677195     History of Changes
Other Study ID Numbers: TxESI 12-001
First Submitted: August 29, 2012
First Posted: August 31, 2012
Results First Submitted: December 14, 2015
Results First Posted: January 21, 2016
Last Update Posted: April 19, 2016